openPR Logo
Press release

Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 Report

05-07-2018 07:54 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Tyrosine Kinase Inhibitors Market & Clinical

“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:

* Introduction to Cancer Tyrosine Kinase Inhibitors
* Signaling Pathway of Receptor Tyrosine Kinase
* Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
* Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
* Global Tyrosine Kinase Inhibitors Market Overview
* Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
* Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
* Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
* Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Tyrosine-Kinase-Inhibitors-Market-&-Clinical-Pipeline-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors



2. Tyrosine Kinase: An Overview



3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies



4. Types of Tyrosine Kinase Receptors

4.1 Epidermal Growth Factor Receptor

4.1.1 Types of Epidermal Growth Factor Receptor

4.1.2 Epidermal Growth Factor Receptor & Ligands

4.1.3 Epidermal Growth Factor Receptor & Cancers



4.2 Platelet-Derived Growth Factor Receptor (PDGFR)

4.2.1 Types of Platelet-Derived Growth Factor Receptor

4.2.2 Platelet-Derived Growth Factor Receptor & Ligands

4.2.3 Platelet-Derived Growth Factor Receptor & Cancer



4.3 Insulin-Like Growth Factor 1 Receptor (IGF-1R)

4.3.1 Insulin-Like Growth Factor 1 Receptor & its Ligands

4.3.2 Insulin-Like Growth Factor 1 Receptor & its role in Cancer



5. Signaling Pathway of Receptor Tyrosine Kinase

5.1 PI3K/Akt Pathway

5.2 Ras/Raf/ERK1/2 Pathway

5.3 The JAK/STAT Pathway



6. Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer



7. BCR-ABL Tyrosine Kinase Inhibitors

7.1 Imatinib

7.2 Nilotinib

7.3 Dasatinib

7.4 Ponatinib

7.5 Bosutinib



8. Epidermal Growth Factor Receptor Kinase Inhibitors Tyrosine

8.1 Gefitinib

8.2 Erlotinib

8. 3 Lapatinib

8.4 Icotinib

8.5 Canertinib

8.6 Afatinib

8.7 Neratinib

8.8 Poziotinib



9. Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

9.1 Sunitinib

9.2 Sorafenib

9.3 Vandetanib

9.4 Pazopanib

9.5 Axitinib

9.6 Cediranib



10. Applications of Tyrosine Kinase Inhibitor in Cancer Therapy

10.1 Role of Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

10.2 Mitigation of Chronic Myeloid Leukaemia

10.3 Role of tyrosine Kinase Inhibitors in Combating Colorectal Cancer

10.4 Gastrointestinal Cancer & Tyrosine Kinase Inhibitor

10.5 Tyrosine Kinase Inhibitor in Breast Cancer



11. Global Tyrosine Kinase Inhibitors Market Overview

11.1 Current Market Scenario

11.2 Cancer Tyrosine Kinase Inhibitors Pipeline Overview



12. Global Tyrosine Kinase Inhibitor Market Dynamics

12.1 Favorable Driving Factors

12.1.1 Research & Development

12.1.2 Strong Clinical Pipeline

12.1.3 Increasing Disease Incidences

12.1.4 Unmet Requirement of Completely Curative Agents

12.1.5 Advancement in Manufacturing Capabilities of the Biopharmaceutical Companies



12.2 Challenges Countered by Tyrosine Kinase Inhibitor Market

12.2.1 Strict Regulatory Guidelines for Approval of Prospective Drug

12.2.2 Long Phase of Research & Development

12.2.3 Funding of Clinical Trials

12.2.4 Highly Competitive Market



13. Global Tyrosine Kinase Inhibitor Market Future Prospects



14. Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase

14.1 Unknown

14.2 Research

14.3 Preclinical

14.4 Clinical

14.5 Phase-I

14.6 Phase-I/II

14.7 Phase-II

14.8 Phase-II/III

14.9 Phase-III

14.10 Preregistration

14.11 Registered



15. Marketed Cancer Tyrosine Kinase Inhibitors Clinical Insight by Brand Name, Company & Indication

15.1 Blood Cancer

15.1.1 Ibrutinib (Imbruvica)

15.1.2 Ponatinib (Iclusig)

15.1.3 Dasatinib (Tasigna)

15.1.4 Nilotinib (Tasigna)

15.1.5 Bosutinib (Bosulif)

15.1.6 Radotinib (Supect)



15.2 Breast Cancer

15.2.1 Trastuzumab Subcutaneous (Herceptin SC)

15.2.2 Pertuzumab (Omnitarg & Perjeta)

15.2.3 Lapatinib (Tykerb & Tyverb)

15.2.4 Trastuzumab Biosimilar (CANMAb & Hertraz)

15.2.5 Trastuzumab Biosimilar (Vivitra)



15.3 Gastric Cancer

15.3.1 Apatinib



15.4 Non-small cell lung cancer

15.4.1 Afatinib (Gilotrif, Giotrif & Tomtovok)

15.4.2 Nintedanib (Ofev & Vargatef)

15.4.3 Ceritinib (Zykadia)

15.4.4 Crizotinib (Xalkori)

15.4.5 Icotinib (Conmana)

15.4.6 Gefitinib (Iressa)

15.4.7 Alectinib (Alecensa)



15.5 Renal Cancer

15.5.1 Axitinib (Inlyta)



15.6 Thyroid Cancer

15.6.1 Vandetanib (Caprelsa, Zactima & Zictifa)



15.7 Multiple

15.7.1 Sunitinib (Sutent)

15.7.2 Lenvatinib (Lenvima)

15.7.3 Regorafenib (Stivarga)

15.7.4 Imatinib (Gleevec, Glivec & Ruvise)

15.7.5 Trastuzumab (Herceptin)

15.7.6 Erlotinib (Tarceva)

15.7.7 Ramucirumab (Cyramza)

15.7.8 Cabozantinib (COMETRIQ, Cabometyx & Cometriq)

15.7.9 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM,

Theraloc & VECTHIX)

15.7.10 Sorafenib (Nexavar)

15.7.11 Imatinib (Imatib)



16. Discontinued & Suspended Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company & Phase

16.1 No Development Reported

16.2 Discontinued

16.3 Suspended



17. Competitive Landscape

17.1 AB Science

17.2 Advenchen Laboratories

17.3 Array BioPharma

17.4 ARIAD Pharmaceuticals

17.5 Astellas Pharma (OSI Pharmaceuticals)

17.6 AstraZeneca

17.7 Bayer HealthCare

17.8 Biocad

17.9 Biocon

17.10 Boehringer Ingelheim

17.11 Bristol-Myers Squibb

17.12 Celera Genomics Group

17.13 Celgene Corporation (Avila Therapeutics)

17.14 Celltrion

17.15 Chugai Pharmaceutical

17.16 Cytopia Research

17.17 Daiichi Sankyo (Ambit Biosciences Corporation)

17.18 Dyax

17.19 Eisai Co Ltd

17.20 Exelixis

17.21 GlaxoSmithKline

17.22 Hanmi Pharmaceutical

17.23 Novartis

17.24 Onyx Pharmaceuticals

17.25 Pfizer

17.26 Plexxikon

17.27 Reliance Life Sciences

17.28 Roche

17.29 Shire

17.30 Synthon

17.31 Wyeth

17.32 Xcovery

17.33 Zydus Cadila

Figure 3-1: Pictorial View of Signaling Pathways Involved on Activation of Tyrosine Kinase Receptor

Figure 4-1: Different Types of Tyrosine Kinase Receptors

Figure 5-1: Various Possible Signaling Pathways Taken by Receptor Tyrosine Kinase

Figure 5-2: Steps Involved in PI3K/Akt Pathway

Figure 5-3: Signaling Pathway Followed by Ras/Raf/ERK1/2 Pathway

Figure 5-4: Signaling Pathway of JAK STAT Tyrosine Kinase Receptors

Figure 10-1: Applications of Tyrosine Kinase Inhibitors in Cancer Therapy

Figure 11-1: Global Cancer Kinase Inhibitors Market Opportunity (US$ Billion), 2015-2020

Figure 11-2: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (%), 2016

Figure 11-3: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (Numbers), 2016

Figure 11-4: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (%), 2016

Figure 11-5: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (Numbers), 2016

Figure 12-1: Various Driving Factors Involved in Establishment of Tyrosine Kinase Inhibitor Market

Figure 12-2: List of the Drugs In Different Phases of Clinical Trials

Figure 12-3: List of Main Challenges Which Hamper Development of Tyrosine Kinase Inhibitors

Figure 17-1: AB Scicence - Clinical Pipeline

Figure 17-2: Advenchen Laboratories - Clinical Pipeline

Figure 17-3: ARIAD - Clinical Pipeline

Figure 17-4: Biocon - linical Pipeline

Figure 17-5: Celgene Corporation - Clinical Pipeline

Figure 17-6: Daiichi Sankyo - Clinical Pipeline

Figure 17-7: Novartis - Clinical Pipeline

Figure 17-8: Plexxikon - Clinical Pipeline

Figure 17-9: Roche - Clinical Pipeline

Figure 17-10: Zydus Cadila - Clinical Pipeline



Table 3-1: Recently Approved Tyrosine Kinase Inhibitors

Table 4-1: ErbB Family Members & Their Ligands

Table 4-2: Platelet-Derived Growth Factor Receptor & Ligands

Table 4-3: Receptor Platelet Derived Tyrosine Kinase & the Cancers Associated

Table 4-4: Insulin Receptor Family Members & Its Ligands

Table 7-1: List of Tyrosine Kinase Inhibitors Developed against BCR-ABL Receptors

Table 8-1: List of the Drugs Targeting EFGR Receptor

Table 9-1: Different Drugs associated with The Treatment of Angiogenesis Related Cancers

Table 10-1: Tyrosine Kinase Inhibitors Targeting Lung Cancer

Table 10-2: Drugs being Developed to Treat Hematological Malignancies

Table 10-3: Drugs Used to Manage Breast Cancer

Table 10-4: Some of the Tyrosine Kinase Inhibitors Developed to Treat Metastatic Melanoma

Table 11-1: Drugs to Enter the Market in Near Future

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 Report here

News-ID: 1040828 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Kinase

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Manufacturers …
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market Research 2018 A market study "Global Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Market" examines the performance of the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market 2018. It encloses an in-depth Research of the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 market state and the competitive landscape Globally. This report analyzes the potential of Dual Specificity Mitogen Activated
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK …
ReportsWorldwide has announced the addition of a new report title Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Tyrosine Protein Kinase CSK - Pipeline Review, H2 2017'; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or
MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integ …
ReportsWorldwide has announced the addition of a new report title MAP Kinase Interacting SerineThreonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (SerineThreonine K …
ReportsWorldwide has announced the addition of a new report title Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (SerineThreonine Kinase MNB or MNBDYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or
Aurora Kinase A (Aurora 2 or SerineThreonine Protein Kinase 15 or SerineThreonin …
ReportsWorldwide has announced the addition of a new report title Aurora Kinase A (Aurora 2 or SerineThreonine Protein Kinase 15 or SerineThreonine Protein Kinase 6 or SerineThreonine Protein Kinase Aurora A or AuroraIPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2017'; Aurora Kinase
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Inte …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “MAP Kinase Interacting Serine/Threonine Protein Kinase 1 - Pipeline Review, H2 2017”, constitutes close to 7 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report MAP Kinase Interacting SerineThreonine Protein Kinase 1 - Pipeline Review, H2 2017, outlays comprehensive information on